SG11201806905UA - Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers - Google Patents

Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

Info

Publication number
SG11201806905UA
SG11201806905UA SG11201806905UA SG11201806905UA SG11201806905UA SG 11201806905U A SG11201806905U A SG 11201806905UA SG 11201806905U A SG11201806905U A SG 11201806905UA SG 11201806905U A SG11201806905U A SG 11201806905UA SG 11201806905U A SG11201806905U A SG 11201806905UA
Authority
SG
Singapore
Prior art keywords
peptides
international
combination
co7k
march
Prior art date
Application number
SG11201806905UA
Inventor
Andrea Mahr
Oliver Schoor
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SG11201806905UA publication Critical patent/SG11201806905UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111 HO 11111 011131001111111101111101111111011110111111 International Bureau .. .... ..Yejd .... ...,,, (10) International Publication Number (43) International Publication Date WO 2017/157972 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CO7K 7/06 (2006.01) C07K 16/28 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 38/17 (2006.01) CO7K 7/08 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 39/00 (2006.01) CO7K 14/47 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/EP2017/056049 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 15 March 2017 (15.03.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1604458.8 16 March 2016 (16.03.2016) GB kind of regional protection available): ARIPO (BW, GH, 62/308,944 16 March 2016 (16.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tilbingen (DE). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, L (72) Inventors: MAHR, Andrea; Kirschenweg 22, 72076 V, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Tubingen (DE). SCHOOR, Oliver; Eichhaldenstrasse 19, GW, KM, ML, MR, NE, SN, TD, TG). _ 72074 Tubingen (DE). WEINSCHENK, Toni; Im Mor- — genrain 15, 73773 Aichwald (DE). Published: _ (74) Agent: KRAUI3, Jan; BOEHMERT & BOEHMERT, — with international search report (Art. 21(3)) = Pettenkoferstrasse 22, 80336 Munich (DE). — with sequence listing of description (Rule 5.2(a)) part = = = = = = = = = = = = 1-1 ei IN tz. IN in (54) Title: PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL 11 LUNG CANCER AND OTHER CANCERS (57) : The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In ::::) particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associ - ei ated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active phar - 0 maceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
SG11201806905UA 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers SG11201806905UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308944P 2016-03-16 2016-03-16
GBGB1604458.8A GB201604458D0 (en) 2016-03-16 2016-03-16 Peptides and combination of peptides for use in immunotherapy against cancers
PCT/EP2017/056049 WO2017157972A1 (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

Publications (1)

Publication Number Publication Date
SG11201806905UA true SG11201806905UA (en) 2018-09-27

Family

ID=55952389

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202006119TA SG10202006119TA (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201806905UA SG11201806905UA (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202006119TA SG10202006119TA (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

Country Status (31)

Country Link
US (4) US20170296641A1 (en)
EP (2) EP4180450A1 (en)
JP (2) JP2019515650A (en)
KR (2) KR20180121530A (en)
CN (1) CN108779149A (en)
AU (3) AU2017235364B2 (en)
BR (1) BR112018017022A2 (en)
CA (1) CA3016410A1 (en)
CL (2) CL2018002591A1 (en)
CO (1) CO2018010009A2 (en)
CR (1) CR20180491A (en)
DK (1) DK3430027T3 (en)
EA (1) EA201891701A1 (en)
ES (1) ES2965011T3 (en)
FI (1) FI3430027T3 (en)
GB (1) GB201604458D0 (en)
HR (1) HRP20231570T1 (en)
HU (1) HUE064592T2 (en)
IL (1) IL261785A (en)
LT (1) LT3430027T (en)
MA (2) MA43719B1 (en)
MD (1) MD3430027T2 (en)
MX (1) MX2018011215A (en)
PE (1) PE20181824A1 (en)
PH (1) PH12018501865A1 (en)
PL (1) PL3430027T3 (en)
PT (1) PT3430027T (en)
RS (1) RS64907B1 (en)
SG (2) SG10202006119TA (en)
SI (1) SI3430027T1 (en)
WO (1) WO2017157972A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116731156A (en) * 2016-03-16 2023-09-12 伊玛提克斯生物技术有限公司 Transfected T cells and T cell receptors for cancer immunotherapy
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (en) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers
EP3539562A1 (en) 2018-03-12 2019-09-18 Eberhard Karls Universität Tübingen Medizinische Fakultät Immunotherapeutic peptides
DE102018108612A1 (en) * 2018-03-21 2019-09-26 Immatics US, Inc. METHOD FOR INCREASING PERSISTENCE OF ADOPTIVELY INFUNDED T CELLS
US20220073630A1 (en) * 2018-12-28 2022-03-10 Hoffmann-La Roche, Inc. A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
EA202193139A1 (en) 2019-05-27 2022-03-01 Имматикс Юс, Инк. VIRAL VECTORS AND THEIR APPLICATIONS IN ADOPTIONAL CELL THERAPY
JP2022535421A (en) 2019-06-06 2022-08-08 イマティクス バイオテクノロジーズ ゲーエムベーハー Screening by counterselection using sequence similar peptides
DE102019121007A1 (en) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
JP2024502034A (en) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． CD8 polypeptides, compositions, and methods of using them
DE102021100038A1 (en) 2020-12-31 2022-06-30 Immatics US, Inc. MODIFIED CD8 POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF
CN113087801B (en) * 2021-04-07 2022-07-05 深圳市核子基因科技有限公司 Kit for jointly detecting lung cancer by using nucleic acid and antibody
JP2024516699A (en) 2021-05-05 2024-04-16 イマティクス バイオテクノロジーズ ゲーエムベーハー BMA031 antigen-binding polypeptide
CN114230636B (en) * 2021-11-12 2023-04-25 四川大学 Polypeptide and application thereof, and medicine containing polypeptide
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115785207A (en) * 2022-06-10 2023-03-14 河北博海生物工程开发有限公司 Lung cancer specific molecular target 02 and application thereof
CN115785208A (en) * 2022-06-10 2023-03-14 河北博海生物工程开发有限公司 Lung cancer specific molecular target 01 and application thereof
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041741A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
ES2304398T3 (en) * 2000-07-31 2008-10-16 Green Peptide Co., Ltd. ANTIGEN OF TUMORS.
RU2007135030A (en) * 2005-02-24 2009-03-27 Симайнз, Инк. (Us) COMPOSITIONS AND METHODS FOR CLASSIFICATION OF BIOLOGICAL SAMPLES
CN105566450A (en) * 2007-07-27 2016-05-11 伊玛提克斯生物技术有限公司 Novel immunogenic epitopes for immunotherapy
PL2119726T5 (en) * 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Novel and powerful MHC-class II peptides derived from survivin and neurocan
WO2011066265A1 (en) * 2009-11-25 2011-06-03 Ludwig Institute For Cancer Research Ltd. Cancer testis antigens as biomarkers in non-small cell lung cancer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CN101870725B (en) * 2010-06-29 2012-06-27 郑州大学 MAGE (Melanoma Antigen Gene)-4 anti-tumor CTL (Cytotoxic T Lymphocyte) epitope peptide and application thereof
CA2847332A1 (en) * 2011-08-31 2013-03-07 Mie University Vaccine preparation for cancer treatment
TWI777198B (en) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015172843A1 (en) * 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
CN105219714A (en) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 A kind of test kit for activating lung cancer specific immune response

Also Published As

Publication number Publication date
HRP20231570T1 (en) 2024-03-15
CL2018002591A1 (en) 2018-11-05
FI3430027T3 (en) 2023-11-29
CR20180491A (en) 2019-01-09
US20240123044A1 (en) 2024-04-18
KR20180121530A (en) 2018-11-07
CN108779149A (en) 2018-11-09
MD3430027T2 (en) 2024-03-31
CO2018010009A2 (en) 2018-09-28
MX2018011215A (en) 2018-11-22
EP4180450A1 (en) 2023-05-17
PH12018501865A1 (en) 2019-07-15
GB201604458D0 (en) 2016-04-27
ES2965011T3 (en) 2024-04-10
PE20181824A1 (en) 2018-11-29
CL2023001346A1 (en) 2023-10-06
HUE064592T2 (en) 2024-03-28
EP3430027A1 (en) 2019-01-23
AU2017235364B2 (en) 2022-01-06
CA3016410A1 (en) 2017-09-21
IL261785A (en) 2018-10-31
BR112018017022A2 (en) 2019-02-05
EP3430027B1 (en) 2023-09-13
MA43327A1 (en) 2018-12-31
WO2017157972A1 (en) 2017-09-21
US20170296641A1 (en) 2017-10-19
DK3430027T3 (en) 2023-12-04
EA201891701A1 (en) 2019-02-28
AU2022202307B2 (en) 2022-09-15
JP2019515650A (en) 2019-06-13
AU2017235364A1 (en) 2018-10-25
AU2022287621A1 (en) 2023-02-02
JP2023055722A (en) 2023-04-18
MA43719A (en) 2018-11-28
PL3430027T3 (en) 2024-03-04
RS64907B1 (en) 2023-12-29
LT3430027T (en) 2023-11-27
AU2022202307A1 (en) 2022-04-28
US20200085930A1 (en) 2020-03-19
US20240100137A1 (en) 2024-03-28
SI3430027T1 (en) 2024-01-31
KR20230004914A (en) 2023-01-06
PT3430027T (en) 2023-12-15
MA43719B1 (en) 2023-11-30
SG10202006119TA (en) 2020-08-28

Similar Documents

Publication Publication Date Title
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201807300PA (en) Uterine cancer treatments
SG11201806951TA (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201807868VA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201801384YA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201801670YA (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG11201806577UA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG11201801756WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201809781PA (en) Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201808783XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201808629UA (en) Immunotherapy against melanoma and other cancers
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201808797XA (en) T cell receptors